A study by Alexander Thompson, PhD of the Centre for Cancer Research and Cell Biology, Queen’s University of differential gene expression in cytogenetically normal subtype of acute myeloid leukemia cells reveals a HOX/TALE signature that may have specific prognostic value. Direct gene targeting of HOXA/PBX3 sensitizes these cells to standard chemotherapy, laying a foundation for a novel therapeutic strategy.
Blog - In the News
Using Partek Software in Leukemia ResearchFebruary 3, 2014
Kennedy Krieger Institute and Partek Awarded $1.8M NIH GrantMay 22, 2013
Partek Incorporated, in collaboration with the Kennedy Krieger Institute, has been awarded a phase II Small Business Innovation Research (SBIR) grant in the amount of $1.8M by the National Institutes of Health (NIH) to develop commercial software which will analyze human genetic changes and illuminate chromosomal abnormalities underlying conditions such as autism spectrum disorder (ASD), bipolar disorder, and schizophrenia.
Kennedy Krieger and Partek Incorporated Discover Novel Method to Reveal Genetic Relatedness Between IndividualsNovember 15, 2011
At a time when profound gaps remain in our understanding of how one person’s genes differ from another person’s, developing accurate methods to interpret the human genome is essential to uncover population history, population relationships and the genetic basis of some of the most common diseases affecting society.